Clinical Trial Update: TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for TAVT-45 (Abiraterone Acetate) granules in metastatic prostate cancer patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• TAVT-45 (Abiraterone Acetate)

Snippet

Sponsor: Tavanta Therapeutics | Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-01-16